Ascendis Pharma A/S (BSP:A1SN34) COGS-to-Revenue : 0.08 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ascendis Pharma A/S COGS-to-Revenue?

Ascendis Pharma A/S's Cost of Goods Sold for the three months ended in Mar. 2024 was R$41 Mil. Its Revenue for the three months ended in Mar. 2024 was R$519 Mil.

Ascendis Pharma A/S's COGS to Revenue for the three months ended in Mar. 2024 was 0.08.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ascendis Pharma A/S's Gross Margin % for the three months ended in Mar. 2024 was 92.11%.

Ascendis Pharma A/S COGS-to-Revenue Historical Data

The historical data trend for Ascendis Pharma A/S's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S COGS-to-Revenue Chart

Ascendis Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.45

0.24

0.17

Ascendis Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.14	0.27	0.15	0.14	0.08

Ascendis Pharma A/S COGS-to-Revenue Calculation

Ascendis Pharma A/S's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	237.216	/	1425.153
	=	0.17

Ascendis Pharma A/S's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	40.97	/	519.058
	=	0.08

Ascendis Pharma A/S (BSP:A1SN34) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ascendis Pharma A/S's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	40.97 / 519.058
	=	92.11 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Ascendis Pharma A/S COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma A/S (BSP:A1SN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (BSP:A1SN34) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ASND:USA ASND:Mexico A71:Germany

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

http://www.ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (BSP:A1SN34) Headlines

No Headlines